New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences
New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences
New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
2 nd Annual Essentials in Primary Care<br />
Fall Conference<br />
Friday, November 11, <strong>2011</strong><br />
<strong>Drug</strong> Interactions<br />
Linagliptin – Tradjenta<br />
• Linagliptin is a weak to moderate inhibitor of CYP isozyme<br />
CYP3A4, but does not inhibit other CYP isozymes and is not an<br />
inducer of CYP isozymes.<br />
• Linagliptin is a P-glycoprotein (P-gp) substrate, and inhibits P-<br />
gp mediated transport of digoxin at high concentrations.<br />
Based on the results of limited drug interaction studies,<br />
linagliptin is considered unlikely to cause interactions with<br />
P-gp substrates at therapeutic concentrations.<br />
• Inducers of CYP3A4 or P-gp (e.g., rifampin) decrease exposure<br />
to linagliptin to subtherapeutic and likely ineffective<br />
concentrations. For patients requiring use of such drugs, an<br />
alternative to linagliptin is strongly recommended.<br />
Linagliptin – Tradjenta<br />
Clinical Trials Monotherapy:<br />
• 496 patients mean A1c 8.0 treated with<br />
linagliptin 5 mg QD vs. placebo for 24 weeks<br />
– A1c -0.4% linagliptin (L) vs. +0.3% placebo (P)<br />
(difference from placebo -0.7%)<br />
– Patients achieving A1c